DEBT (Tables)

9 Months Ended

Jun. 30, 2025

Debt Disclosure [Abstract]

Schedule of Long-Term Debt and Effective Interest Rates

Long-term debt as of June 30, 2025 and September 30, 2024 is detailed in the table below.

	June 30, 2025		September 30, 2024
Seller Note – Bolder BioPath (related party)	$	207	$	376
Seller Note – Preclinical Research Services	—		464
Seller Payable - Orient BioResource Center	3,235		3,700
Seller Note – Histion (related party)	—		84
Second Lien Notes	21,816		17,846
Convertible Senior Notes	114,754		109,979
Term Loan Facility, DDTL and Incremental Term Loans	269,167		272,840
Total debt before unamortized debt issuance costs	$	409,179	$	405,289
Less: Debt issuance costs not amortized	(12,637)		(11,950)
Total debt, net of unamortized debt issuance costs	$	396,542	$	393,339
Less: Current portion	(6,206)		(3,538)
Total Long-term debt	$	390,336	$	389,801

Below are the weighted-average effective interest rates for the loans available under the Credit Agreement:

	Three Months Ended June 30,				Nine Months Ended June 30,
	2025		2024		2025		2024
Effective interest rates:
Term Loan	11.41	%	11.67	%	11.55	%	11.43	%
Initial DDTL	11.39	%	11.66	%	11.53	%	11.41	%
Additional DDTL	11.52	%	11.78	%	11.66	%	11.54	%